Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Surgical Management of Early-Onset Breast Cancer Among Young BRCA1 and BRCA2 Carriers.
Journal: JAMA network open
Published: August 26, 2026
Sentinel Lymph Node Biopsy for Patients With cN1 HR+/HER2- Breast Cancer and Palpable Adenopathy: A Nonrandomized Clinical Trial.
Journal: JAMA surgery
Published: May 06, 2026
Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 16, 2026
Radiation therapy management in BRCA1/2 carriers diagnosed with early breast cancer: An international cohort study.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: February 08, 2026
Radiation therapy management in BRCA1/2 carriers diagnosed with early breast cancer: An international cohort study.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: February 08, 2026
ASO Visual Abstract: Trends in Patient-Reported Outcomes After Breast-Conserving Surgery and Partial-Breast Versus Whole-Breast Irradiation.
Journal: Annals of surgical oncology
Published: October 15, 2025
Trends in Patient-Reported Outcomes After Breast-Conserving Surgery and Partial-Breast Versus Whole-Breast Irradiation.
Journal: Annals of surgical oncology
Published: March 04, 2025
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study.
Journal: The Lancet. Oncology
Published: January 07, 2025
Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer.
Journal: bioRxiv : the preprint server for biology
Published: September 10, 2024
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.
Journal: Nature
Published: April 03, 2024
Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers.
Journal: NPJ breast cancer
Published: November 17, 2023
Mutational Status is Associated with a Higher Rate of Pathologic Complete Response After Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer.
Journal: Annals of surgical oncology
Published: July 06, 2023
Last Updated: 09/26/2026